Table 6

Chemotherapy Associated With QT Prolongation

Chemotherapy AgentsIncidence (%)Frequency of Use
Histone deacetylase inhibitor
 Vorinostat (Zolinza) (10,131)3.5–6+
 Arsenic trioxide (Trisenox) (10,163–170)26–93+
Small molecule tyrosine kinase inhibitors
 Dasatinib (Sprycel) (10)<1–3++
 Lapatinib (Tykerb) (10)16+
 Nilotinib (Tasigna) (171–173)1–10+

For an explanation of the + symbols, please see Table 1.

  • The incidence of QT prolongation varies widely in the literature for arsenic due to the differences in study design, definition of QT prolongation, and numbers of patients. Medication manufacturers and locations: Trisenox, Cephalon Oncology, Frazer, Pennsylvania; Tasigna, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; others as in Tables 1 and 4.